Search
Lifecore Biomedical Inc
LFCRAdd to Watchlist
4.720USD
-0.010-0.21%
Close 08-14 16:00（ET）Quotes delayed by 15 min
177.93MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Lifecore Biomedical Inc is 8.00, ranking 59 out of 156 in the Pharmaceuticals industry. The average price target is 8.75, with a high of 10.00 and a low of 7.50.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
6.750
Target Price
+42.71%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Lifecore Biomedical Inc
LFCR
5
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Regeneron Pharmaceuticals Inc
REGN
30
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Lifecore Biomedical Inc's expected revenue for the next quarter?
Lifecore Biomedical Inc's expected revenue is 32.02M.
What is Lifecore Biomedical Inc's price target?
Analysts forecast that Lifecore Biomedical Inc's price target is USD 8.75, with the highest forecast at USD 10.00 and the lowest forecast at USD 7.50.
How have Lifecore Biomedical IncLFCR's recent earnings per share performed?
The market expectation was USD -0.19, while Lifecore Biomedical IncLFCR's earnings per share (EPS) for the previous quarter was USD -0.43. EPS for the next quarter is expected at USD -0.22.
What is the analyst rating for Lifecore Biomedical Inc?
Based on the ratings of Lifecore Biomedical Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.